| Schedule of Potentially Dilutive Securities Not Considered for Calculation of Diluted Net Loss Per Share |
Potentially dilutive securities not considered for the calculation of diluted net loss per share are as follows (in common stock equivalents):
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30, |
|
|
|
2026 |
|
|
2025 |
|
Common stock options and restricted stock units |
|
|
13,976,293 |
|
|
|
9,734,321 |
|
Employee stock purchase plan |
|
|
38,241 |
|
|
|
46,883 |
|
Total |
|
|
14,014,534 |
|
|
|
9,781,204 |
|
|
| Summary of Significant Expense Categories Reviewed by CODM |
The table below summarizes the significant expense categories regularly reviewed by our CODM for the three and six months ended June 30, 2026 and 2025.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
|
|
|
2026 |
|
|
2025 |
|
|
|
2026 |
|
|
2025 |
|
Research and development expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Efzofitimod expenses |
|
$ |
2,106 |
|
|
$ |
12,290 |
|
|
|
|
5,641 |
|
|
|
21,094 |
|
Preclinical development and other shared research and development expenses |
|
|
4,230 |
|
|
|
2,623 |
|
|
|
|
7,585 |
|
|
|
5,184 |
|
Non-cash expenses (depreciation and stock-based compensation) |
|
|
412 |
|
|
|
471 |
|
|
|
|
839 |
|
|
|
920 |
|
Total research and development expenses |
|
|
6,748 |
|
|
|
15,384 |
|
|
|
|
14,065 |
|
|
|
27,198 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General and administrative expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Other general and administrative expenses |
|
|
3,232 |
|
|
|
3,928 |
|
|
|
|
6,307 |
|
|
|
6,992 |
|
Non-cash expenses (depreciation and stock-based compensation) |
|
|
901 |
|
|
|
1,001 |
|
|
|
|
1,945 |
|
|
|
1,896 |
|
Total general and administrative expenses |
|
|
4,133 |
|
|
|
4,929 |
|
|
|
|
8,252 |
|
|
|
8,888 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other segment items (1) |
|
|
571 |
|
|
|
781 |
|
|
|
|
1,215 |
|
|
|
1,673 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated net loss |
|
$ |
(10,310 |
) |
|
$ |
(19,532 |
) |
|
|
$ |
(21,102 |
) |
|
$ |
(34,413 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Other segment items includes interest income and interest expense. |
|
|